Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology:
The Second National AIDS Malignancy Conference
USC/Norris Cancer Hospital, Los Angeles, CA 90033
BACKGROUND: AIDS-lymphoma is the second most common malignancy in patients with HIV infection. First line combination chemotherapy is associated with complete remission in approximately 50%. No standard second line therapy has been defined in relapsed or refractory patients. We wished to explore the efficacy of pegylated L-asparaginase (Oncaspar) in this patient population. Oncaspar has previously shown efficacy against high grade lymphoid malignancies.
METHODS: Four dose levels of Oncaspar are being studied in relapsed/refractory AIDS-NHL. The dose for cohort 1 is 1500 IU/m2 given IM every two weeks.
RESULTS: Thus far, two patients have been accrued. Their characteristics and study results are shown below: Table
Both patients have had biopsy-proven complete disease resolution. Adverse effects consisted of low fibrinogen, prolonged APTT, and moderate fatigue in both; mild nausea, anorexia, and elevated cholesterol in one patient.
CONCLUSION: We conclude that Oneaspar has good preliminary evidence of anti-tumor activity in patients with refractory AIDS-NHL within minimal side effects. Accrual is ongoing.
Bethesda, Maryland April 6-8, 1998
Sponsored by the National Cancer Institute